0.00Open2.25Pre Close0 Volume1 Open Interest3.50Strike Price0.00Turnover999.17%IV-19.62%PremiumJan 17, 2025Expiry Date2.46Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.5660Delta0.2699Gamma0.39Leverage Ratio-0.0410Theta-0.0005Rho-0.22Eff Leverage0.0006Vega
Immunic Stock Discussion
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Tuesday, 7th January at 6:30 am
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April –
– Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 –
– Strengthened Management Team and Board of Directors with Key Hir...
Anything Important?
No comment yet